Châtillon, France, March 27, 2025 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut...
Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent...
• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma...
Company to Host Conference Call Today, March 27, at 4:30pm ETBOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune...
-Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer-...
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer...
A global collaboration agreement has been signed for the development and commercialization of a Granzyme B-targeted Positron Emission Tomography (PET)...
Pioneering cancer immunology company Asgard strengthens leadership team as it progresses its lead asset AT-108 towards clinical trials Shane brings...
AGOURA HILLS, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”),...
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, March 25, 2025 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company developing...
Updated time slot of 11:00 AM CT on Friday, March 28, 2025PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS...
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies...
First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with...
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S....
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting...
First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian...
Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate...
– Latest BOND-003 data show 75.5% of patients achieved a complete response at any time –– Median duration of response...
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of...